Piperazine D3 and 5-HT2a receptor modulators

Details for Australian Patent Application No. 2009294695 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Gobbi, Luca; Jaeschke, Georg; Rodriguez Sarmiento, Rosa Maria; Steward, Lucinda

Agent Spruson & Ferguson

Pub. Number AU-B-2009294695

PCT Pub. Number WO2010/031735

Priority 08164802.4 22.09.08 EP

Filing date 11 September 2009

Wipo publication date 25 March 2010

Acceptance publication date 13 September 2012

International Classifications

C07D 261/20 Heterocyclic compounds having nitrogen and oxygen as the only ring hetero atoms

A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61P 25/00 Drugs for disorders of the nervous system

A61P 25/22 Drugs for disorders of the nervous system

A61P 25/24 Drugs for disorders of the nervous system

A61P 25/28 Drugs for disorders of the nervous system

A61P 25/30 Drugs for disorders of the nervous system

C07D 413/12 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 493/08 Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system

Event Publications

10 March 2011 PCT application entered the National Phase

  PCT publication WO2010/031735 Priority application(s): WO2010/031735

13 September 2012 Application Accepted

  Published as AU-B-2009294695

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009294697-Method of cooling a hydrocarbon stream and an apparatus therefor

2009294680-Novel antibody formulation